Established in the summer of 2021, PrimeLink Bio has raised a RMB 150 million angel funding round from Vertex Ventures, Fosun, Kaitai Capital, etc.

PrimeLink Bio is an innovative biopharmaceutical company dedicated to the development of next-generation antibody-drug conjugates (ADCs). Upholding the core philosophy of "tailoring the optimal ADC structure for each target," the company has independently developed the  next-generation ADC technology platform named ENHANMIX®. Leveraging the exceptional hydrophilicity, compatibility, and flexibility of ENHANMIX®, PrimeLink Bio is comprehensively advancing a diverse ADC pipeline covering multiple novel drug modalities, committed to bringing its self-developed First-in-class and Best-in-class products to the global market.

Our founders have over 20 years of experience in drug delivery platforms and antibody-drug conjugate (ADC) development, covering the entire process and multi-field professional expertise from early drug discovery to clinical trials. PrimeLink Bio will combine various resources from China and the United States to develop, step-by-step promote our technology and eventually deliver our drugs to the world.

PrimeLink Bio has been honored with multiple prestigious awards, including recognition as one of the “Top 100 Chinese Pharmaceutical Innovation Value Discovery Enterprises (2022~2023),” designation as a national-level “Technology-Based SME,” as well as titles such as Shenzhen “Innovative SME,” “Specialized and Sophisticated SME,” and “Seed Unicorn Enterprise.” The company was also recognized as an “Outstanding Enterprise” in the 13th China Innovation and Entrepreneurship Competition. These accolades highlight the company’s innovation strength and growth potential.